tirzepatide china Lilly's Weight-Loss Drug Approved in Amid Race With Novo Analysis of the Advantages of

The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection a novel disease-modifying osteoarthritis drug

0.1% (placebo) Steady State: Achieved after 4-5 weeks of weekly dosing Safety: Nausea (68% at 4.5 mg), vomiting (32%), generally mild-moderate and transient Discontinuation: 14% discontinued due to GI adverse events Appetite Effects: Significant reductions in Visual Analogue Scale (VAS) hunger scores Publication: Lau DCW, et al

If you become pregnant whilst taking retatrutide, stop the study drug and contact your study team and GP urgently

Retrieved August 1, 2026